Free Trial
TSE:TH

Theratechnologies (TH) Stock Price, News & Analysis

C$1.97
+0.02 (+1.03%)
(As of 07/12/2024 08:53 PM ET)
Today's Range
C$1.90
C$2.05
50-Day Range
C$1.66
C$2.14
52-Week Range
C$1.22
C$4.60
Volume
15,901 shs
Average Volume
28,727 shs
Market Capitalization
C$90.58 million
P/E Ratio
N/A
Dividend Yield
3.76%
Price Target
C$5.50

Theratechnologies MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
179.2% Upside
C$5.50 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
-0.65mentions of Theratechnologies in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.90 out of 5 stars

TH stock logo

About Theratechnologies Stock (TSE:TH)

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

TH Stock Price History

TH Stock News Headlines

Theratechnologies (TSE:TH) Announces Earnings Results
Central Bank Gold Heist In Progress
Central Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire investors are buying right along with them. Even Warren Buffett put over $500 million into gold. And with the help of a tax and penalty-free "Trump Loophole, " these investors are investing retirement into gold and other precious metals without having to put up any of their own cash. In our Free Retirement Protection Kit, we reveal all the details on how the rich use this loophole to protect and growth their retirement wealth in any economy…and show you how you can use it too.
Central Bank Gold Heist In Progress
Central Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire investors are buying right along with them. Even Warren Buffett put over $500 million into gold. And with the help of a tax and penalty-free "Trump Loophole, " these investors are investing retirement into gold and other precious metals without having to put up any of their own cash. In our Free Retirement Protection Kit, we reveal all the details on how the rich use this loophole to protect and growth their retirement wealth in any economy…and show you how you can use it too.
Here's what Wall Street expects from Theratechnologies's earnings report
7THTX : Theratechnologies Earnings Preview
See More Headlines
Receive TH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Theratechnologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/10/2024
Today
7/15/2024
Next Earnings (Estimated)
9/24/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
103
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
C$5.50
High Stock Price Target
C$5.50
Low Stock Price Target
C$5.50
Potential Upside/Downside
+179.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
C$-18,000,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$78.10 million
Cash Flow
C$0.52 per share
Book Value
C($0.54) per share

Miscellaneous

Free Float
N/A
Market Cap
C$90.58 million
Optionable
Not Optionable
Beta
1.81
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Paul Lévesque (Age 59)
    President, CEO & Director
    Comp: $1.6M
  • Mr. Philippe Dubuc M.B.A. (Age 57)
    MBA, Senior VP & CFO
    Comp: $587.17k
  • Mr. Jocelyn Lafond L.L.M. (Age 56)
    LL.B., General Counsel & Corporate Secretary
    Comp: $429.6k
  • Dr. Christian Marsolais Ph.D. (Age 61)
    Senior VP & Chief Medical Officer
    Comp: $590.29k
  • Mr. John Leasure (Age 59)
    Global Commercial Officer
    Comp: $571.68k
  • Hon. Andre Dupras M.Sc. (Age 60)
    Vice President of Human Resources

TH Stock Analysis - Frequently Asked Questions

How have TH shares performed this year?

Theratechnologies' stock was trading at C$2.14 at the beginning of 2024. Since then, TH shares have decreased by 7.9% and is now trading at C$1.97.
View the best growth stocks for 2024 here
.

How were Theratechnologies' earnings last quarter?

Theratechnologies Inc. (TSE:TH) issued its quarterly earnings data on Wednesday, July, 10th. The company reported $0.03 earnings per share for the quarter. The firm earned $30 million during the quarter. Theratechnologies had a negative net margin of 23.04% and a negative trailing twelve-month return on equity of 1,116.86%.

How do I buy shares of Theratechnologies?

Shares of TH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Theratechnologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Theratechnologies investors own include Stars Group (TSGI), BCE (BCE), ProMetic Life Sciences (PLI), Teranga Gold (TGZ), Nemaska Lithium (NMX).

This page (TSE:TH) was last updated on 7/15/2024 by MarketBeat.com Staff

From Our Partners